Dayvigo HSA/FSA Eligibility and Submission: How to Pay Less for Lemborexant in 2026

Is Dayvigo Covered by HSA and FSA Accounts?

Dayvigo qualifies for reimbursement from a Health Savings Account (HSA) and a Flexible Spending Account (FSA) because it is a legally obtained prescription drug in the United States. Under IRS Publication 502, prescription medicines are qualified medical expenses. That rule applies whether you pay at a retail pharmacy, a mail-order pharmacy, or through a telehealth platform.

The short version: keep your receipt and pharmacy label. Both documents are the primary evidence you need to file a reimbursement claim.

What IRS Publication 502 Actually Says

The IRS defines a qualified medical expense as an amount paid "for the diagnosis, cure, mitigation, treatment, or prevention of disease." A written prescription from a licensed clinician satisfies that definition for any FDA-approved drug. FDA approval of lemborexant was granted in December 2019 under NDA 212028. That approval establishes lemborexant's legal status as a prescription medicine, which is the criterion IRS Pub. 502 requires.

Over-the-counter sleep aids such as diphenhydramine do NOT automatically qualify without a prescription. Dayvigo, by contrast, is never sold OTC. Every fill is by definition a prescription transaction, removing any ambiguity about eligibility.

HSA vs. FSA: Practical Differences for Dayvigo

Both account types allow Dayvigo reimbursement, but they differ in flexibility. HSA funds roll over indefinitely and can be invested; FSA funds typically expire December 31 (or at the end of a grace period). If you have a choice, using HSA funds for a recurring prescription like Dayvigo preserves FSA dollars for time-sensitive items such as vision or dental care.

A Limited-Purpose FSA (LPFSA), which some employers pair with an HSA, covers only dental and vision expenses by default. Prescription drugs fall outside an LPFSA unless your plan document specifically adds a prescription drug benefit. Check your Summary Plan Description before submitting a Dayvigo claim to an LPFSA.

How to Submit a Dayvigo Claim to Your HSA or FSA

Submission steps are straightforward, though the exact portal differs by administrator. The core documentation requirement is the same across virtually all plan administrators: an itemized receipt or Explanation of Benefits (EOB) that shows the drug name, date of service, and amount paid.

Step 1: Gather Your Documents

You need at minimum three items.

• The pharmacy receipt showing the drug name "lemborexant" or "Dayvigo," the dispensing date, the quantity, and the dollar amount you paid.
• The pharmacy label from the bottle, which confirms the prescribing physician and your name.
• A Letter of Medical Necessity (LMN) is NOT routinely required for prescription drugs under IRS Pub. 502, but some FSA third-party administrators ask for one anyway. Having a brief note from your prescriber on file speeds up any audit.

If your insurer processed the claim, an EOB replaces the receipt as the primary document.

Step 2: Log into Your Administrator Portal

Major HSA/FSA administrators include Optum Bank, HealthEquity, WageWorks (now Inspira Financial), and Fidelity. Each has a mobile app and a web portal where you can upload a photo of your receipt. Processing time is typically 3 to 5 business days.

Step 3: Use Your HSA/FSA Debit Card at the Pharmacy

The fastest method is to pay directly with your HSA or FSA debit card at the pharmacy counter. The card automatically codes the transaction as a qualified medical expense at pharmacies with a valid IIAS (Inventory Information Approval System). Most retail chains (CVS, Walgreens, Rite Aid, Costco Pharmacy) use IIAS. If the card is declined because the system cannot verify the Rx status, pay out of pocket and then submit for reimbursement through the portal.

Step 4: Keep Records for Three Years

The IRS can audit HSA distributions for up to three years after filing. Store pharmacy receipts, EOBs, and any LMN documentation. A simple PDF folder organized by tax year is adequate.

What Dayvigo Actually Costs Without Insurance

Cash prices matter because they set the baseline for calculating your HSA/FSA savings and for understanding how much any discount program actually helps.

Without insurance, a 30-tablet supply of Dayvigo 10 mg retails for approximately $430 to $510 at major US pharmacies as of early 2026. The 5 mg formulation is priced comparably; dose-based pricing differences are typically under $20 per fill. These prices fluctuate with pharmacy contracts and do not reflect any manufacturer rebates passed to the plan.

At the federal HSA contribution limit of $4,300 for individuals in 2025 (IRS Rev. Proc. 2024-25), a single individual paying $480 per fill spends roughly $5,760 annually on Dayvigo alone. That exceeds the HSA limit, which is why stacking multiple discount strategies is worth the effort.

Eisai Manufacturer Savings Programs

Eisai, the maker of Dayvigo, has historically offered a copay assistance program for commercially insured patients and a separate patient assistance program for uninsured or underinsured patients. Program terms change frequently, so the authoritative source is always eisai.us or the phone number printed on the Dayvigo packaging.

Copay Assistance Card

Commercially insured patients (those with private insurance, not Medicare or Medicaid) may qualify for a copay card that reduces their cost-sharing to as low as $10 to $30 per fill, subject to eligibility rules and monthly or annual caps. The card is typically loaded digitally or mailed as a physical card. You present it at the pharmacy alongside your insurance card.

Copay assistance cards do NOT count as an HSA-qualified contribution, and payments made by the copay card do NOT qualify for HSA/FSA reimbursement. Only the amount you actually pay out of pocket is reimbursable. If the copay card covers your entire cost, there is nothing left to submit to your HSA or FSA.

Patient Assistance Program

Patients without insurance or with very high deductibles may qualify for the Eisai Patient Assistance Program (PAP). Income thresholds and documentation requirements vary by year. The NeedyMeds database and the Partnership for Prescription Assistance are two public directories that list current PAP availability, though Eisai's own site is the definitive source.

Stacking Strategy: The Correct Order of Operations

Getting the lowest possible net cost requires applying discount sources in the right sequence.

1. Apply commercial insurance first. Insurance pays its contracted rate; you owe only your deductible, copay, or coinsurance.
2. Apply the Eisai copay assistance card second, if eligible. This reduces or eliminates your share.
3. Pay any remaining balance with your HSA or FSA debit card. Only this remaining amount qualifies for tax-advantaged reimbursement.
4. Submit receipts or use auto-pay features to document the HSA/FSA transaction.

Skipping step 2 and going straight to HSA/FSA means leaving manufacturer savings on the table. Applying step 3 before step 2 creates an administrative tangle: if the copay card later reimburses costs you already submitted to an FSA, you have effectively received a double tax benefit, which is not permitted under IRS rules.

The Pharmacology Behind the Cost: Why Lemborexant Commands a Premium

Understanding why no generic exists helps set realistic expectations about price.

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks OX1R and OX2R, the receptors for the wake-promoting neuropeptide orexin (also called hypocretin). By blocking orexin signaling at sleep onset, lemborexant reduces the "wake drive" rather than sedating the central nervous system nonselectively. That mechanism distinguishes it from older benzodiazepines and from Z-drugs such as zolpidem.

The key SUNRISE-1 trial (N=291) demonstrated statistically significant reductions in subjective sleep onset latency at both 5 mg and 10 mg doses at Week 1 and Week 4 compared to placebo (Karppa et al., Sleep Medicine, 2020). The SUNRISE-2 trial (N=949) showed sustained efficacy over 12 months, with significantly improved sleep onset and maintenance versus placebo and versus zolpidem tartrate extended release 6.25 mg (Murphy et al., Sleep Medicine, 2022). No generic manufacturer has filed an ANDA (Abbreviated New Drug Application) for lemborexant; patent protection is expected to run through the late 2030s, maintaining the branded-only pricing environment.

Schedule V Classification and Prescription Requirements

The DEA classifies Dayvigo as Schedule V, the lowest level of controlled substance scheduling (DEA diversion control). Most states allow Schedule V prescriptions to be transmitted electronically or by phone (unlike Schedule II, which requires a written Rx). That means telehealth prescribers can generally order Dayvigo and send it directly to a pharmacy without a paper prescription, reducing access friction.

The Schedule V designation does not affect HSA/FSA eligibility. Controlled substances are not excluded from IRS Pub. 502 as long as the drug is legally prescribed.

Comparison to Suvorexant (Belsomra)

Suvorexant (Belsomra, Merck) is the other FDA-approved DORA and entered the market in 2014. A generic suvorexant became available in 2023, which pushed Belsomra's cash price significantly lower. Some insurers have moved suvorexant generic to a preferred tier, making prior authorization for Dayvigo more common. If your insurer requires a prior authorization (PA) for Dayvigo, your prescriber will need to document a clinical reason for preferring lemborexant over generic suvorexant. Documented differences in half-life (lemborexant 17 to 19 hours vs. Suvorexant 12 hours) and receptor selectivity profile may support that case (Rosenberg et al., Sleep, 2019).

Navigating Prior Authorization for Dayvigo

Prior authorization is not a denial. It is a documentation request. Most PA approvals for Dayvigo fall into one of three scenarios.

Scenario 1: Step Therapy

The insurer requires that you try a less expensive option (typically zolpidem, eszopiclone, or now generic suvorexant) before approving Dayvigo. If you have already tried those agents and experienced inadequate response or intolerable side effects, your prescriber documents that history and submits it with the PA form. Adequately documented step therapy failures are approved at high rates.

Scenario 2: Safety Exception

Patients on CNS depressants, patients with complex drug interactions, or patients in whom lower-sedation profiles are clinically preferred may qualify for a safety exception. Lemborexant's mechanism avoids GABA-A potentiation, which is relevant for patients sensitive to respiratory depression (Beuckmann et al., J Pharmacol Exp Ther, 2017).

Scenario 3: Appeals

If the initial PA is denied, you have a right to appeal under the Affordable Care Act's internal and external review provisions. Your prescriber submits a letter of medical necessity citing the SUNRISE-2 trial data and the clinical rationale. Published data from the American Journal of Managed Care suggest that PA appeals for insomnia medications are granted at rates between 40% and 60% when supported by adequate clinical documentation.

During the PA process, you may pay cash and request HSA/FSA reimbursement for any fills you purchase while the PA is pending, as long as all other IRS Pub. 502 requirements are met.

Insomnia as a Diagnosed Condition: Why the Diagnosis Matters for Coverage

Insomnia disorder, as defined by DSM-5 criteria, is a recognized medical diagnosis. DSM-5 requires symptoms for at least 3 nights per week for at least 3 months, causing clinically significant distress or impairment. That formal diagnosis is the bridge between your symptoms and insurance coverage, prior authorization approval, and Letters of Medical Necessity.

The American Academy of Sleep Medicine (AASM) Clinical Practice Guideline for insomnia, last updated in 2017, conditionally recommends lemborexant for chronic insomnia disorder in adults, rating the evidence as "low" quality due to limited long-term data at the time of the guideline (Sateia et al., JCSM, 2017). The SUNRISE-2 data published after the guideline strengthen the evidence base. Current AASM guidance still recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, with pharmacotherapy used when CBT-I is unavailable, insufficient, or declined by the patient.

Having an insomnia diagnosis in your medical record also simplifies HSA/FSA audit defense. If the IRS ever questions whether Dayvigo was purchased for medical or general wellness purposes, the formal diagnosis and the prescription together establish the medical purpose beyond any reasonable doubt.

Pharmacy Options and Price Variation

Cash prices for Dayvigo vary by pharmacy. GoodRx and similar comparison tools pull real-time contracted prices from pharmacy benefit managers. As of early 2026, prices for 30 tablets of Dayvigo 10 mg range from roughly $390 (Costco) to $510 (independent retail), depending on your ZIP code and the PBM contract the pharmacy has negotiated.

Mail-order pharmacy (90-day supply) can reduce per-fill cost by 15% to 25% if your insurance includes mail-order pharmacy benefits. A 90-day supply also reduces pharmacy dispensing fees from three fills to one. For HSA/FSA purposes, a 90-day supply qualifies for a single larger reimbursement transaction, which is administratively simpler than three monthly submissions.

Specialty pharmacies are not typically required for Dayvigo; it is stocked at most retail chains. If your insurer routes you to a specialty pharmacy for cost-control reasons, verify the specialty pharmacy accepts HSA/FSA debit cards before filling. Most do, but call ahead.

The 2024 IRS limit on FSA contributions was $3,200 per employee (IRS Rev. Proc. 2023-34). Annual Dayvigo costs at cash price may approach or exceed that cap. If you are contributing to a Healthcare FSA specifically to cover Dayvigo, plan your contribution election during open enrollment with the annual cost in mind, remembering the use-it-or-lose-it rule.